Rani Therapeutics Files 8-K for Regulation FD Disclosure
Ticker: RANI · Form: 8-K · Filed: Jul 12, 2024 · CIK: 1856725
| Field | Detail |
|---|---|
| Company | Rani Therapeutics Holdings, Inc. (RANI) |
| Form Type | 8-K |
| Filed Date | Jul 12, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulation-fd, disclosure
Related Tickers: RANI
TL;DR
Rani Therapeutics (RANI) filed an 8-K for a Reg FD disclosure, details TBD.
AI Summary
Rani Therapeutics Holdings, Inc. filed an 8-K on July 12, 2024, to report a Regulation FD Disclosure. The filing does not contain specific details about the nature of the disclosure, dollar amounts, or other parties involved.
Why It Matters
This filing indicates Rani Therapeutics is making a public disclosure under Regulation FD, which requires companies to share material information broadly.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for a Regulation FD disclosure and does not contain specific financial or operational information that would immediately indicate high risk.
Key Players & Entities
- Rani Therapeutics Holdings, Inc. (company) — Registrant
- July 12, 2024 (date) — Filing Date
FAQ
What is the specific nature of the Regulation FD disclosure made by Rani Therapeutics?
The provided filing does not specify the details of the Regulation FD disclosure, only that one was made on July 12, 2024.
Are there any material events or transactions being reported in this 8-K filing?
The filing is categorized as a Regulation FD Disclosure, but the specific material events are not detailed within the provided text.
Does this 8-K filing involve any new agreements, financings, or legal proceedings?
The filing does not provide information on specific agreements, financings, or legal proceedings; it only indicates a Regulation FD disclosure.
What is the significance of a Regulation FD Disclosure for Rani Therapeutics?
A Regulation FD disclosure means Rani Therapeutics is making material information available to the public, preventing selective disclosure to certain parties.
Where is Rani Therapeutics Holdings, Inc. headquartered?
Rani Therapeutics Holdings, Inc. is headquartered at 2051 Ringwood Avenue, San Jose, California, 95131.
Filing Stats: 514 words · 2 min read · ~2 pages · Grade level 13.3 · Accepted 2024-07-12 17:19:32
Key Financial Figures
- $0.0001 — tered Class A common stock, par value $0.0001 per share RANI The Nasdaq Stock Mar
Filing Documents
- rani-20240712.htm (8-K) — 35KB
- 0000950170-24-083284.txt ( ) — 149KB
- rani-20240712.xsd (EX-101.SCH) — 25KB
- rani-20240712_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. Rani Therapeutics Holdings, Inc. (the "Company"), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it had recently engaged in discussions with various investors to explore a potential equity financing. After evaluating ongoing business development discussions and financing opportunities and its cash position, business outlook and market conditions, the Company has elected not to move forward with an equity financing at this time. The Company will continue to evaluate its cash needs and business outlook, and it may seek additional equity financing in the future. All of the information furnished in this Item 7.01 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Rani Therapeutics Holdings, Inc. Date: July 12, 2024 By: /s/ Svai Sanford Svai Sanford Chief Financial Officer